Journal Club PowerPoint Template. A Question of Therapy RCT
|
|
- Alicia Brooke Franklin
- 6 years ago
- Views:
Transcription
1 Journal Club PowerPoint Template A Question of Therapy RCT 1
2 EBM Process Ask a well built (focused) clinical question Search for the best evidence to answer the question Critically appraise the evidence Apply the evidence to the patient 2
3 Case Presentation 61y F w HTN, HFpEF, DM, CKD 4 presented to ED after labs in clinic revealed acute on chronic renal failure and hyperkalemia. Pt c/o SOB related to recent CAP for which she had just completed Abx. Pt treated for several days with kayexylate, and high dose IV lasix with minimal response and worsening renal function 3
4 Search Strategy Why you chose your article article given to me by renal colleagues as evidence our plan of ultrafiltration was a bad idea Describe your search strategy Cochrane for heart failure ultrafiltration Results of your search 5 studies were found which compared UF with diuretics 4
5 Reference Bart BA, MD et al. Ultrafiltration in Decompensated Heart Failure with Cardiorenal Syndrome. NEJM. Nov. 6,
6 Article Conclusion The use of stepped pharmacologictherapy (diuretics) was superior to ultrafiltration in preservation of renal function with similar weight loss at 96 hours. Ultrafiltration was associated with a higher rate of adverse events. 6
7 Critically Appraise the Evidence Are the Results Valid? What are the results? Do the Results Apply to my patient and the patients in my practice? 7
8 Are the results valid? Were the patients randomized? Yes Was randomization concealed? Yes Study design: Automated Web-based system, patients were randomly assigned in 1:1 ratio. Permuted block, stratification in clinical sites. 8
9 Are the Results Valid? Were patients similar at baseline with respect to prognostic factors? Probably Table 1: Some differences as expected with small sample size of 188 pts. Ultrafiltration: older, lower wt, EF. More ischemia, A-fib, on ACE, BNP, Bblockers,ACE, Pharm: More chf hosp in last year, DM, BUN, Cr All quartile ranges overlap 9
10 Are the Results Valid? Were all 5 groups blinded (pt, clinicians, data collectors, outcome assessors, data analystist)? No this would be impossible to do Discussion/limitations: Treatment assignments not blinded, biases of investigators may have effected treatment. 10
11 Are the Results Valid? How complete was follow-up? Fairly complete 2 patients in ultrafiltration group not included in 1 endpoint due to lack of baseline Cr (1) and lack of all post baseline Cr levels (1). 11
12 Are the Results Valid? Was the trial stopped early for benefit? No. The study was stopped early for worse outcomes and higher adverse event rate in the ultrafiltration group. Stopped at 188 pt (planned 200 pt) 12
13 Are the Results Valid? Were patients analyzed in the groups to which they were randomized (Intention to treat)? Yes No difference in cross over 18% in Pharm 23% in UF 13
14 What are the Results? 1 Endpoint Pharm Ultrafiltration P Value Cr change Wt 5.5kg 5.7kg 0.58 change (12.1 lb) (12.6 lb) 14
15 What are the results? 2 Endpoints No diff in worsening 7 days: (Definition of Composite Endpoint of Worsening Condition : death, dialysis, adverse events, persistent CHF. No sig difference rehospitalizations for HR, or any. No sig difference in dyspnea or global well-being (96 hr, 7 d, discharge) 15
16 What are the Results? Adverse Events: kidney failure, bleeding, IV catheter complications including infection (all: HF,CV problems, anemia, lytes) Serious Adverse Events 60 d Pharm UF P value 57% 72% % 17%
17 What are the results? Calculations: Adverse Events ARI RRI NNH 57%-72% = 15%/57% = 1/.15 15% 26% 6.7 If you treat 7 people with ultrafiltration 1 additional person will have a serious adverse event compared to diuretic tx. 17
18 What are the results? How precise were the results? No confidence intervals Probably not due to small sample size 18
19 Applicability Were the study patients similar to my patient? No. The study would not have included this particular patient But, many of our CHF patients would be included 19
20 Applicability Was duration of follow-up adequate? Yes days 1,2,3,4,7,30, and 60 20
21 Applicability Were all clinically important outcomes considered? 1 outcomes: weight and serum creatinine 2 outcomes: worsened condition during treatment, crossover, death, rehospitalization, ED or acute clinic visits 96hr changes in: clinical decongestion, Na, Hgb, BNP, BUN, GFR, Pt score of well-being, Pt SOB, Total net fluid loss Change in furosemide-equivalent dose from preadmission to discharge 21
22 Applicability Are the benefits worth the costs and potential risks? No. Study showed that the UF group had more adverse events without significantly better outcomes This was different from other 4 studies in lit. (N = 200, 100, 30, 19) 22
23 GRADE: Quality of Evidence RCTs start high 5 limitations can lower confidence Biases in design and execution Concealment, blinding, ITT, loss to follow up Indirectness Surrogate or physiologic outcomes Inconsistency Variability in results (heterogeneity) Imprecision Small numbers, low power, wide confidence intervals Reporting or publication bias Funnel plot
24 Grading Recommendations: Strong recommendations Strong Methods Large precise effect Few downsides of therapy Weak recommendations Weak methods Imprecise estimate Small effect Substantial downsides
25 Strength of Recommendation STRONG or WEAK STRONG: Benefits clearly outweigh risks/hassles/cost Risk/hassles/costs clearly outweigh benefits WEAK There is a close or uncertain balance between benefits and risks/hassles/costs Based on low quality evidence
26 Conclusion Will I change my practice based on this evidence? No In this case, Cardiology proceeded with ultrafiltration (she is now on dialysis) Renal advised against ultrafiltration The FM team wanted dialysis from the start 26
Recognizing and Treating Patients with the Cardio-Renal Syndrome
Recognizing and Treating Patients with the Cardio-Renal Syndrome Joachim H. Ix, MD, MAS, FASN Professor of Medicine Chief; Division of Nephrology-Hypertension University of California San Diego 1 Conflicts
More informationPivotal Role of Renal Function in Acute Heart failure
Pivotal Role of Renal Function in Acute Heart failure Doron Aronson MD, FESC Department of Cardiology RAMBAM Health Care Campus Haifa, Israel Classification and definitions of cardiorenal syndromes CRS
More informationCase Presentation. This presentation is the intellectual property of the author. Contact them for permission to reprint and/or distribute.
Worsening Renal Function in Heart Failure Patients Mark Drazner, MD, MSc Clinical Chief of Cardiology Medical Director, CHF/VAD/Transplant James M. Wooten Chair in Cardiology UT Southwestern Medical Center
More informationOvercoming the Cardiorenal Syndrome
Overcoming the Cardiorenal Syndrome October 29, 2016 Randall C Starling MD MPH FACC FESC FHFSA FHFA Professor of Medicine Heart & Vascular Institute Cleveland Clinic Lerner College of Medicine Cleveland
More informationEBM: Therapy. Thunyarat Anothaisintawee, M.D., Ph.D. Department of Family Medicine, Ramathibodi Hospital, Mahidol University
EBM: Therapy Thunyarat Anothaisintawee, M.D., Ph.D. Department of Family Medicine, Ramathibodi Hospital, Mahidol University How to appraise therapy literature Are the result valid? What are the result?
More informationCardio-Renal Syndrome in Acute Heart Failure:
Cardio-Renal Syndrome in Acute Heart Failure: Target for Therapy Marvin A. Konstam, M.D. Research support and/or consulting relevant to this lecture: Merck, Otsuka, Johnson & Johnson; Amgen; Cardiokine
More informationUltrafiltration in Decompensated Heart Failure. Description
Subject: Ultrafiltration in Decompensated Heart Failure Page: 1 of 7 Last Review Status/Date: September 2016 Ultrafiltration in Decompensated Heart Failure Description Ultrafiltration is a technique being
More informationThe Art and Science of Diuretic therapy
The Art and Science of Diuretic therapy Dr. Fayez EL Shaer Associate Professour of cardiology Consultant cardiologist MD, MSc, PhD, CBNC, NBE FESC, ACCP, FASNC,HFA KKUH, KFCC Heart failure: fluid overload
More informationThe Cardiorenal Syndrome in Heart Failure
The Cardiorenal Syndrome in Heart Failure Van N Selby, MD Assistant Professor of Medicine Advanced Heart Failure Program, UCSF October 9, 2015 Disclosures None 1 Cardiorenal Syndrome (CRS) A pathophysiologic
More informationCardiorenal and Renocardiac Syndrome
And Renocardiac Syndrome A Vicious Cycle Cardiorenal and Renocardiac Syndrome Type 1 (acute) Acute HF results in acute kidney injury Type 2 Chronic cardiac dysfunction (eg, chronic HF) causes progressive
More informationIntroduzione al metodo GRADE
Introduzione al metodo GRADE Atto Billio MD, MSc EBHC Ematologia e TMO-Bolzano Gruppo linee guida SIE Critique of EBM De-emphasizes patient values Doesn t account for individual variation Devalues clinical
More informationHeart Failure and Renal Disease Cardiorenal Syndrome
Advanced Heart Failure: Clinical Challenges Heart Failure and Renal Disease Cardiorenal Syndrome 17 th Apr 2015 Ju-Hee Lee, M.D Cardiovascular Center, Chungbuk National University Hospital Chungbuk National
More informationUltrafiltration in Decompensated Heart Failure. Description
Subject: Ultrafiltration in Decompensated Heart Failure Page: 1 of 9 Last Review Status/Date: September 2014 Ultrafiltration in Decompensated Heart Failure Description Ultrafiltration is a technique being
More informationCASE STUDIES IN ADVANCED HEART FAILURE
CASE STUDIES IN ADVANCED HEART FAILURE Navin Rajagopalan, MD Director, Congestive Heart Failure Medical Director, Cardiac Transplantation Gill Heart Institute, Cardiovascular Medicine DISCLOSURES NOTHING
More informationFrom PARADIGM-HF to Clinical Practice. Waleed AlHabeeb, MD, MHA Associate Professor of Medicine President of the Saudi Heart Failure Group
From PARADIGM-HF to Clinical Practice Waleed AlHabeeb, MD, MHA Associate Professor of Medicine President of the Saudi Heart Failure Group PARADIGM-HF: Inclusion Criteria Chronic HF NYHA FC II IV with LVEF
More informationManagement of Advanced Systolic Heart Failure. Robert W. Hull MD FACC Associate Professor of Medicine West Virginia University
Management of Advanced Systolic Heart Failure Robert W. Hull MD FACC Associate Professor of Medicine West Virginia University American College of Cardiology Foundation (ACCF) American Heart Association
More informationMortality as an Efficacy or Safety Endpoint : Lessons Learned from the Heart Failure Trials
Mortality as an Efficacy or Safety Endpoint : Lessons Learned from the Heart Failure Trials Christopher M. O Connor, MD Professor of Medicine Director, Duke Heart Center Acting Chief, Division of Cardiology
More informationJournal Club September 29, Vanessa AKIKI PGYlII Internal Medicine
Journal Club September 29, 2017 Vanessa AKIKI PGYlII Internal Medicine AUBMC 2017 Case Presentation 41-year-old man who was diagnosed with type 1 diabetes 21 years ago presents to your clinic. He believes
More informationManagement of Acute Heart Failure
Management of Acute Heart Failure Uri Elkayam, MD Professor of Medicine University of Southern California School of Medicine Los Angeles, California elkayam@usc.edu ADHF Treatments Goals.2 Improve symptoms.
More informationHeart Failure and Renal Failure. Gerasimos Filippatos, MD, FESC, FHFA President HFA
Heart Failure and Renal Failure Gerasimos Filippatos, MD, FESC, FHFA President HFA Definition Epidemiology Pathophysiology Management (?) Recommendations for NHLBI in cardiorenal interactions related to
More informationCritical Review Form Therapy Objectives: Methods:
Critical Review Form Therapy Clinical Trial Comparing Primary Coronary Angioplasty with Tissue-Plasminogen Activator for Acute Myocardial Infarction (GUSTO-IIb), NEJM 1997; 336: 1621-1628 Objectives: To
More informationLITERATURE REVIEW: HEART FAILURE. Chief Residents
LITERATURE REVIEW: HEART FAILURE Chief Residents Heart Failure EF 40% HFrEF Problem with contractility EF 40-50% HFmrEF EF > 50% HFpEF Problem with filling/relaxation RISK FACTORS Post MI HTN DM Obesity
More informationHow to Interpret a Clinical Trial Result
How to Interpret a Clinical Trial Result Edward V. Loftus, Jr., M.D. Professor of Medicine Division of Gastroenterology and Hepatology Mayo Clinic College of Medicine Rochester MN CP123456-1 Are results
More informationHypertension in 2015: SPRINT-ing ahead of JNC-8. MAJ Charles Magee, MD MPH FACP Director, WRNMMC Hypertension Clinic
Hypertension in 2015: SPRINT-ing ahead of JNC-8 MAJ Charles Magee, MD MPH FACP Director, WRNMMC Hypertension Clinic Conflits of interest? None Disclaimer The opinions contained herein are not to be considered
More informationTrial to Reduce. Aranesp* Therapy. Cardiovascular Events with
Trial to Reduce Cardiovascular Events with Aranesp* Therapy John J.V. McMurray, Hajime Uno, Petr Jarolim, Akshay S. Desai, Dick de Zeeuw, Kai-Uwe Eckardt, Peter Ivanovich, Andrew S. Levey, Eldrin F. Lewis,
More informationUse of Sacubitril/Valsartan in Heart Failure
Use of Sacubitril/Valsartan in Heart Failure & the PARADIGM-HF trial Sarah Mackenzie, PharmD student, University of Toronto Presentation Outline Overview of: Entresto PARADIGM-HF trial Critical Appraisal
More informationA patient with acute heart failure and renal impairment ACCA Masterclass 2017
A patient with acute heart failure and renal impairment Dr Sofie Gevaert Mister P. J.M., 67-years-old Cardiac risk factors: Ex-smoker, AHT, Type 2 diabetes, BMI 43, Hyperlipidaemia Medical history: 2009:
More informationGRADE. Grading of Recommendations Assessment, Development and Evaluation. British Association of Dermatologists April 2014
GRADE Grading of Recommendations Assessment, Development and Evaluation British Association of Dermatologists April 2014 Previous grading system Level of evidence Strength of recommendation Level of evidence
More informationHEART FAILURE IN WOMEN. Marian Limacher, MD Division of Cardiovascular Medicine University of Florida
HEART FAILURE IN WOMEN Marian Limacher, MD Division of Cardiovascular Medicine University of Florida Outline Epidemiology Clinical Overview Why HF is such a challenge State of the Field Heart Failure Adjudication
More informationWhy is ILCOR moving to GRADE?
1 Why is ILCOR moving to GRADE? Associate Professor Peter Morley Director Medical Education Royal Melbourne Hospital University of Melbourne 10 min 2 3 4 5 6 7 Apart from international consensus Allows
More informationPOLICY PRODUCT VARIATIONS DESCRIPTION/BACKGROUND RATIONALE DEFINITIONS BENEFIT VARIATIONS DISCLAIMER CODING INFORMATION REFERENCES POLICY HISTORY
Original Issue Date (Created): June 18, 2007 Most Recent Review Date (Revised): March 25, 2014 Effective Date: July 17, 2014 POLICY PRODUCT VARIATIONS DESCRIPTION/BACKGROUND RATIONALE DEFINITIONS BENEFIT
More informationDifficult to Treat Hypertension
Difficult to Treat Hypertension According to Goldilocks JNC 8 Blood Pressure Goals (2014) BP Goal 60 years old and greater*- systolic < 150 and diastolic < 90. (Grade A)** BP Goal 18-59 years old* diastolic
More informationClinical research in AKI Timing of initiation of dialysis in AKI
Clinical research in AKI Timing of initiation of dialysis in AKI Josée Bouchard, MD Krescent Workshop December 10 th, 2011 1 Acute kidney injury in ICU 15 25% of critically ill patients experience AKI
More informationMedical Policy An Independent Licensee of the Blue Cross and Blue Shield Association
Ultrafiltration in Decompensated Heart Failure Page 1 of 9 Medical Policy An Independent Licensee of the Blue Cross and Blue Shield Association Title: Ultrafiltration in Decompensated Heart Failure Professional
More informationUPDATES IN MANAGEMENT OF HF
UPDATES IN MANAGEMENT OF HF Jennifer R Brown MD, MS Heart Failure Specialist Medstar Cardiology Associates DC ACP Meeting Fall 2017 Disclosures: speaker bureau for novartis speaker bureau for actelion
More informationUltrafiltration in Decompensated Heart Failure. Description
Subject: Ultrafiltration in Decompensated Heart Failure Page: 1 of 9 Last Review Status/Date: September 2015 Ultrafiltration in Decompensated Heart Failure Description Ultrafiltration is a technique being
More informationContrast-Induced Nephropathy: Evidenced Based Prevention
Contrast-Induced Nephropathy: Evidenced Based Prevention Michael J Cowley, MD, FSCAI Nothing to disclose Contrast-Induced Nephropathy (CIN) Definitions New onset or worsening of renal function after contrast
More informationClinical Epidemiology II: Deciding on Appropriate Therapy
Clinical Epidemiology II: Deciding on Appropriate Therapy 1 Clinical Scenario [UG2B] 65 yo man controlled HTN 6-mo Hx cardioversion-resistant afib Benefit vs risk of long-term anticoagulation:? prevent
More informationDefining and Managing the Cardiorenal Syndrome in Acute Decompensated Heart Failure. Barry M. Massie Professor of Medicine UCSF
Defining and Managing the Cardiorenal Syndrome in Acute Decompensated Heart Failure Barry M. Massie Professor of Medicine UCSF DISCLOSURES Consulting fees: Merck-Novacardia Novartis Bristol Myers Squibb
More informationUpdates in Congestive Heart Failure
Updates in Congestive Heart Failure GREGORY YOST, DO JOHNSTOWN CARDIOVASCULAR ASSOCIATES 1/28/2018 Disclosures Edwards speaker on Sapien3 valves (TAVR) Stages A-D and NYHA Classes I-IV Stage A: High risk
More informationOutline. What is Evidence-Based Practice? EVIDENCE-BASED PRACTICE. What EBP is Not:
Evidence Based Practice Primer Outline Evidence Based Practice (EBP) EBP overview and process Formulating clinical questions (PICO) Searching for EB answers Trial design Critical appraisal Assessing the
More informationObjectives 6/14/2016. Cardiorenal Syndrome: Critical Link Between Heart and Kidney
Cardiorenal Syndrome: Critical Link Between Heart and Kidney Chris M. Bell, ACNP Cardiology Associates of North Mississippi Objectives Review the 5 Subtypes of the Cardiorenal Syndrome (CRS) Discuss the
More informationHeart failure: what should be changed? Prof. Gerasimos Filippatos Attikon University Hospital
Heart failure: what should be changed? Prof. Gerasimos Filippatos Attikon University Hospital Disclosures Chair or Committee Member of trials or registries sponsored by Novartis, Bayer, Cardiorentis, Servier
More informationDual Antiplatelet duration in ACS: too long or too short?
Dual Antiplatelet duration in ACS: too long or too short? Leonardo Bolognese, MD, FESC, FACC Cardiovascular Department, Arezzo, Italy Paradigm Shift the ideal duration of DAPT: a moving target Early (stent-related)
More informationARE THE RESULTS VALID?
ARE THE RESULTS VALID? At the beginning, did intervention and control groups start with the same prognosis? Was randomization process adequate? Was randomization concealed? Were patients in the study groups
More informationEffective Health Care Program
Comparative Effectiveness Review Number 37 Effective Health Care Program Chronic Kidney Disease Stages 1 3: Screening, Monitoring, and Treatment Executive Summary Objectives This systematic review evaluates
More informationWHAT IS ADVANCED HEART FAILURE? James C. Fang, MD, FACC Professor and Chief Cardiovascular Division University of Utah School of Medicine
WHAT IS ADVANCED HEART FAILURE? James C. Fang, MD, FACC Professor and Chief Cardiovascular Division University of Utah School of Medicine Disclosures Data Safety Monitoring Board SOPRANO (J&J), EVALUATE-HF
More informationThe Triple Threat. Cardiac Care in the NT Annual Workshop 2017 is proudly supported by:
The Triple Threat DR KELUM PRIYADARSHANA FRACP CONSULTANT NEPHROLOGIST ROYAL DARWIN HOSPITAL Cardiac Care in the NT Annual Workshop 2017 is proudly supported by: Pathogenesis Diabetes CKD CVD Diabetic
More informationDeterminants of quality: Factors that lower or increase the quality of evidence
Determinants of quality: Factors that lower or increase the quality of evidence GRADE Workshop CBO, NHG and Dutch Cochrane Centre CBO, April 17th, 2013 Outline The GRADE approach: step by step Factors
More informationBiomarkers in the Assessment of Congestive Heart Failure
Biomarkers in the Assessment of Congestive Heart Failure Mid-Regional pro-adrenomedullin (MR-proADM) vs BNP & NT-proBNP as Prognosticator in Heart Failure Patients: Results of the BACH Multinational Trial
More informationACUTE HEART FAILURE. Julie Gorchynski MD, MSc, FACEP, FAAEM. Department of Emergency Medicine Emergency Residency Program UTHSC, San Antonio TCEP 2014
ACUTE HEART FAILURE Julie Gorchynski MD, MSc, FACEP, FAAEM Department of Emergency Medicine Emergency Residency Program UTHSC, San Antonio TCEP 2014 No disclosures Objectives Overview Cases Current Therapy
More information3/2/2017. Identifying the Patient for Advanced Therapies. Why is Identifying the Adv HF patient important? CHF Stages and Steps of Treatment
Identifying the Patient for Advanced Therapies Cindy Bither Chief NP- Adv HF Program Medstar Heart and Vascular Institute Stage A High risk with no symptoms Stage B Structural heart disease, no symptoms
More informationWashington, DC, November 9, 2009 Institute of Medicine
Holger Schünemann, MD, PhD Chair, Department of Clinical Epidemiology & Biostatistics Michael Gent Chair in Healthcare Research McMaster University, Hamilton, Canada Washington, DC, November 9, 2009 Institute
More informationACUTE KIDNEY INJURY. Stuart Linas U. Colorado SOM
ACUTE KIDNEY INJURY Stuart Linas U. Colorado SOM Marked increases in incidence of dialysis-requiring AKI in last decade JASN 24 37 2013 Question 1 Of patients who recover from an episode of AKI, what percentage
More informationCardiorenal Syndrome
SOCIEDAD ARGENTINA DE CARDIOLOGIA Cardiorenal Syndrome Joint session ESC-SAC ESC Congress 2012, Munich César A. Belziti Hospital Italiano de Buenos Aires I have no conflicts of interest to declare Cardiorenal
More informationDisclosures. Advances in Chronic Heart Failure Management 6/12/2017. Van N Selby, MD UCSF Advanced Heart Failure Program June 19, 2017
Advances in Chronic Heart Failure Management Van N Selby, MD UCSF Advanced Heart Failure Program June 19, 2017 I have nothing to disclose Disclosures 1 Goal statement To review recently-approved therapies
More informationDisclosures. Overview. Goal statement. Advances in Chronic Heart Failure Management 5/22/17
Disclosures Advances in Chronic Heart Failure Management I have nothing to disclose Van N Selby, MD UCSF Advanced Heart Failure Program May 22, 2017 Goal statement To review recently-approved therapies
More informationRenal Optimization Strategies Evaluation in Acute Heart Failure (ROSE AHF): A Randomized Clinical Trial
Renal Optimization Strategies Evaluation in Acute Heart Failure (ROSE AHF): A Randomized Clinical Trial Horng H Chen MD on behalf of the NHLBI Heart Failure Clinical Research Network Background AHF + Renal
More informationHeart Failure Update. Bibiana Cujec MD May 2015
Heart Failure Update Bibiana Cujec MD May 2015 Disclosures Participation in clinical trial GUIDE IT (BNP in management of HF) Plan Review of new trials/ccs guidelines Management of heart failure: cases
More informationExperimental Design. Terminology. Chusak Okascharoen, MD, PhD September 19 th, Experimental study Clinical trial Randomized controlled trial
Experimental Design Chusak Okascharoen, MD, PhD September 19 th, 2016 Terminology Experimental study Clinical trial Randomized controlled trial 1 PHASES OF CLINICAL TRIALS Phase I: First-time-in-man studies
More informationCardiorenal Syndrome: What the Clinician Needs to Know. William T. Abraham, MD Director, Division of Cardiovascular Medicine
Cardiorenal Syndrome: What the Clinician Needs to Know William T. Abraham, MD Director, Division of Cardiovascular Medicine Orlando, Florida October 7-9, 2011 Renal Hemodynamics in Heart Failure Glomerular
More informationGRADE. Grading of Recommendations Assessment, Development and Evaluation. British Association of Dermatologists April 2018
GRADE Grading of Recommendations Assessment, Development and Evaluation British Association of Dermatologists April 2018 Previous grading system Level of evidence Strength of recommendation Level of evidence
More informationOCTOBER 7-10 PHILADELPHIA, PENNSYLVANIA
OMED 17 OCTOBER 7-10 PHILADELPHIA, PENNSYLVANIA 29.5 Category 1-A CME credits anticipated ACOFP / AOA s 122 nd Annual Osteopathic Medical Conference & Exposition ACOFP - The Heart of the Matter - An Evidence
More informationAll in the Past? Win K. Shen, MD Mayo Clinic Arizona Controversies and Advances in CV Diseases Cedars-Sinai Heart Institute, MFMER
ICD for NICM All in the Past? Win K. Shen, MD Mayo Clinic Arizona Controversies and Advances in CV Diseases Cedars-Sinai Heart Institute, 2017 2017 MFMER 3686275-1 DISCLOSURE Relevant Financial Relationship(s)
More informationSAFETY IN THE CATH LAB How to Minimise Contrast Toxicity
SAFETY IN THE CATH LAB How to Minimise Contrast Toxicity Dr. Vijay Kunadian MBBS, MD, MRCP Senior Lecturer and Consultant Interventional Cardiologist Institute of Cellular Medicine, Faculty of Medical
More informationCongestive Heart Failure: Outpatient Management
The Chattanooga Heart Institute Cardiovascular Symposium Congestive Heart Failure: Outpatient Management E. Philip Lehman MD, MPP Disclosure No financial disclosures. Objectives Evidence-based therapy
More informationLife After CORAL: What Did CORAL Prove? David Paul Slovut, MD, PhD Co-director TAVR, Dir of Advanced Intervention
Life After CORAL: What Did CORAL Prove? David Paul Slovut, MD, PhD Co-director TAVR, Dir of Advanced Intervention No Relationships to Disclose The Need for Modern Renal Trials Increased rate of RAS diagnosis
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Ultrafiltration in Heart Failure Page 1 of 8 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Ultrafiltration in Heart Failure Professional Institutional Original
More informationIssues to Consider in the Design of Randomized Controlled Trials
Issues to Consider in the Design of Randomized Controlled Trials Jay Wilkinson, MD, MPH Professor of Pediatrics & Epidemiology Miller School of Medicine Seminar Purpose To facilitate an interactive discussion
More informationEvidence Based Medicine
Course Goals Goals 1. Understand basic concepts of evidence based medicine (EBM) and how EBM facilitates optimal patient care. 2. Develop a basic understanding of how clinical research studies are designed
More informationCurrent Role of Renal Artery Stenting in Patients with Renal Artery Stenosis
Current Role of Renal Artery Stenting in Patients with Renal Artery Stenosis Young-Guk Ko, M.D. Severance Cardiovascular Hospital, Yonsei University College of Medicine, Seoul, Korea Etiology Fibromuscular
More informationCase Study #3: Renal Disease 1. Please be concise and use only the space provided. 2. Please cite sources as necessary.
NUT 116BL Winter 2013 Name: Cammane Wun Section: A02 Case Study #3: Renal Disease 50 points 1. Please be concise and use only the space provided. 2. Please cite sources as necessary. 3. You may use your
More informationDiastolic Heart Failure Uri Elkayam, MD
Diastolic Heart Failure Uri Elkayam, MD Professor of Medicine University of Southern California School of Medicine Los Angeles, California elkayam@usc.edu Diastolic Heart Failure Clinical Definition A
More informationAcute Kidney Injury (AKI) How Wise is Early Dialysis in Critically Ill Patients? Modalities of Dialysis
Acute Kidney Injury (AKI) How Wise is Early Dialysis in Critically Ill Patients? A common condition in ICU patients Associated with high mortality and morbidity Renal Replacement Therapy (RRT) is the cornerstone
More informationMINI SYMPOSIUM - EUMASS - UEMASS European Union of Medicine in Assurance and Social Security
MINI SYMPOSIUM - EUMASS - UEMASS European Union of Medicine in Assurance and Social Security Quality of Evidence and Grades of Recommendations in guidelines A role for insurance medicine? Prof. Regina
More informationAtrial Fibrillation Topics for Today. Clinical Controversies Management of Atrial Fibrillation. Atrial Fibrillation in the ER Topics for Today
Clinical Controversies Management of Atrial Fibrillation Yerem Yeghiazarians, M.D. Associate Professor of Medicine Leone-Perkins Family Endowed Chair in Cardiology Atrial Fibrillation Topics for Today
More informationOutline. Outline CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW. Question 1: Which of these patients has CKD?
CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW MICHAEL G. SHLIPAK, MD, MPH CHIEF-GENERAL INTERNAL MEDICINE, SAN FRANCISCO VA MEDICAL CENTER PROFESSOR OF MEDICINE, EPIDEMIOLOGY AND BIOSTATISTICS,
More informationHyponatremia as a Cardiovascular Biomarker
Hyponatremia as a Cardiovascular Biomarker Uri Elkayam, MD Professor of Medicine University of Southern California Keck School of Medicine elkayam@usc.edu Disclosure Research grant from Otsuka for the
More informationCCS Perioperative Guidelines When to order a BNP and What to do with a Positive Troponin
Canadian Society of Internal Medicine Annual Meeting 2017 Toronto, ON CCS Perioperative Guidelines When to order a BNP and What to do with a Positive Troponin Dr. Vikas Tandon Associate Professor, Cardiology
More informationCritical Appraisal Practicum. Fabio Di Bello Medical Implementation Manager
Critical Appraisal Practicum Fabio Di Bello Medical Implementation Manager fdibello@ebsco.com What we ll talk about today: DynaMed process for appraising randomized trials and writing evidence summaries
More informationCopyright GRADE ING THE QUALITY OF EVIDENCE AND STRENGTH OF RECOMMENDATIONS NANCY SANTESSO, RD, PHD
GRADE ING THE QUALITY OF EVIDENCE AND STRENGTH OF RECOMMENDATIONS NANCY SANTESSO, RD, PHD ASSISTANT PROFESSOR DEPARTMENT OF CLINICAL EPIDEMIOLOGY AND BIOSTATISTICS, MCMASTER UNIVERSITY Nancy Santesso,
More informationBest Practices in Acute Care Precepting at the Sharp Chula Vista Medical Center Medicine Rotation
Best Practices in Acute Care Precepting at the Sharp Chula Vista Medical Center Medicine Rotation Pratima Patel, PharmD Clinical Pharmacist Medicine Rotation Preceptor Sharp Chula Vista Medical Center
More informationHeart Failure with Reduced EF. Dino Recchia, MD, FACC, FHFSA
Heart Failure with Reduced EF Dino Recchia, MD, FACC, FHFSA Heart Failure HF is the end phenotype of almost all CV disorders Complex clinical syndrome resulting from any structural or functional impairment
More informationThe CARI Guidelines Caring for Australasians with Renal Impairment. Protein Restriction to prevent the progression of diabetic nephropathy GUIDELINES
Protein Restriction to prevent the progression of diabetic nephropathy Date written: September 2004 Final submission: September 2005 Author: Kathy Nicholls GUIDELINES a. A small volume of evidence suggests
More informationEffective Health Care
Number 5 Effective Health Care Comparative Effectiveness of Management Strategies for Renal Artery Stenosis Executive Summary Background Renal artery stenosis (RAS) is defined as the narrowing of the lumen
More informationAcknowledgements. National Kidney Foundation of Connecticut Mark Perazella. Co-PI Slowing the progression of chronic kidney disease to ESRD
A Practical Approach to Chronic Kidney Disease Management for the Primary Care Practioner: A web-site sponsored by the National Kidney Foundation of Connecticut Robert Reilly, M.D. Acknowledgements National
More informationCKD FOR PRIMARY CARE MINNESOTA ACADEMY OF PHYSICIANS 2017 HEATHER ANN MUSTER, MD MS
CKD FOR PRIMARY CARE MINNESOTA ACADEMY OF PHYSICIANS 2017 HEATHER ANN MUSTER, MD MS PLoS One. 2014 Nov 26;9(11):e110535. Of the 445 PCPs who enrolled at least 10 patients, 19 (4.3%) had >50% likelihood
More informationChristopher M. O Connor, MD, FACC CEO and Executive Director, Inova Heart and Vascular Institute Professor of Medicine (adj.) Duke University Editor
New Strategies in the Management of Acute and Advanced Heart Failure Christopher M. O Connor, MD, FACC CEO and Executive Director, Inova Heart and Vascular Institute Professor of Medicine (adj.) Duke University
More informationEducational Intervention in Chronic Kidney Disease
Educational Intervention in Chronic Kidney Disease Presented by: Megan Lasko NFS 562 Case Study Presentation University of Rhode Island MS in Dietetics February 18, 2017 Presentation Format and Abbreviations
More informationHow to define the target population?
Heart Failure 2011 22-24 May. Gothenburg, Sweden Mortality or morbidity as target in acute heart failure trials How to define the target population? Marco Metra, Brescia The Burden of Acute HF Acute HF
More informationAtrial Fibrillation and Heart Failure: Rate vs. Rhythm Control Time for Re-evaluation
Atrial Fibrillation and Heart Failure: Rate vs. Rhythm Control Time for Re-evaluation ANIL K. BHANDARI, M.D, Director, Electrophysiology and EPS Fellowship Program Good Samaritan Hospital/ Harbor UCLA
More informationCritical Appraisal Series
Definition for therapeutic study Terms Definitions Study design section Observational descriptive studies Observational analytical studies Experimental studies Pragmatic trial Cluster trial Researcher
More informationJournal Club: Fairfax Internal Medicine. Stephanie Shin PGY-2 Bianca Ummat PGY-2 July 27, 2012
Journal Club: Fairfax Internal Medicine Stephanie Shin PGY-2 Bianca Ummat PGY-2 July 27, 2012 S Objective Review EBM basic principles Learn how to apply the principles in critically appraising the article.
More informationAcute Kidney Injury in the Hospitalized Patient
Acute Kidney Injury in the Hospitalized Patient Biff F. Palmer, M.D. Professor of Internal Medicine University of Texas Southwestern Medical Center, Dallas Texas Classification of Acute Kidney Injury 1
More informationNovel Approaches for Recognition and Management of Life Threatening Complications of AKI and CKD: Focus on Acute Cardiorenal Syndromes
Novel Approaches for Recognition and Management of Life Threatening Complications of AKI and CKD: Focus on Acute Cardiorenal Syndromes Peter A. McCullough, MD, MPH Baylor University Medical Center, Dallas
More informationCKD and CVD. Jamal Salameh, MD, FACP, FASN First Coast Nephrology
CKD and CVD Jamal Salameh, MD, FACP, FASN First Coast Nephrology An Epidemic of Kidney Disease Prevalence CKD stages 1-4 10% 1988-94 13% 1999-2004 Coresh, JAMA 298:2038, 2007 Stage 5: GFR
More informationVitals HR 90 BP 125/58 Tmax 98.7F O2 Sat 97% on NC 2L/min BMP SCr 1.78 K 3.9 Gluc 194 A1c 7.5 Cardiac LVEF 55% NTproBNP 9,200 Troponin 0.
ALDOSTERONE ANTAGONIST IN HEART FAILURE WITH PRESERVED EJECTION FRACTION ABBREVIATIONS BMP: basic metabolic panel HPI: history of present illness CAD: coronary artery disease HR: heart rate PINHUI (JUDY)
More informationEBP STEP 2. APPRAISING THE EVIDENCE : So how do I know that this article is any good? (Quantitative Articles) Alison Hoens
EBP STEP 2 APPRAISING THE EVIDENCE : So how do I know that this article is any good? (Quantitative Articles) Alison Hoens Clinical Assistant Prof, UBC Clinical Coordinator, PHC Maggie McIlwaine Clinical
More informationThe role of remote monitoring in preventing readmissions after acute heart failure
The role of remote monitoring in preventing readmissions after acute heart failure October 20, 2017 Randall C Starling MD MPH FACC FAHA FESA FHFSA Professor of Medicine Kaufman Center for Heart Failure
More informationOutline. Outline CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW 7/23/2013. Question 1: Which of these patients has CKD?
CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW MICHAEL G. SHLIPAK, MD, MPH CHIEF-GENERAL INTERNAL MEDICINE, SAN FRANCISCO VA MEDICAL CENTER PROFESSOR OF MEDICINE, EPIDEMIOLOGY AND BIOSTATISTICS,
More information